Drug Database
PN

pneumococcal vaccine (Prevenar 7 / Prevenar / PnC + MPL)

✓ Approved

Pfizer, Inc. · Vaccine · Vaccine

What is pneumococcal vaccine?

pneumococcal vaccine is a vaccine developed by Pfizer, Inc.. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection or subcutaneous injection.

Drug Profile

Brand NamesPrevenar 7, Prevenar, PnC + MPL
CompanyPfizer, Inc.
Drug ClassVaccine
RouteInjectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Pfizer, Inc.

Therapeutic Indications

pneumococcal vaccine is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsOtitis media✓ Approved
Infections and infestationsPneumococcal infection✓ Approved
Ear and labyrinth disordersMiddle ear inflammation✓ Approved

Related Research Articles

PubMedRevista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo2026-11-12

Comparative safety of the 20-valent and the 13-valent pneumococcal vaccines in infants and toddlers: a systematic review and meta-analysis of randomized trials.

Ubaldo Helena Beckhäuser HB, Braga Maria Clara Abreu Vianna MCAV, Silva Elisama da Costa EDC, Lima Lenita de Melo LM

This systematic review and meta-analysis aimed to compare the safety of the 20-valent pneumococcal conjugate vaccine versus the 13-valent pneumococcal vaccine in healthy infants and toddlers. We searched PubMed, Scopus, Embase, and Cochrane on January 20, 2026, for randomized controlled trials comparing the 20-valent pneumococcal conjugate vaccine with the 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers (0-3 years). We computed risk ratios with 95% confidence intervals for all outcomes, using a random-effects model. Heterogeneity was assessed using I2 statistics. Five randomized clinical trials were included, comprising 5,604 patients, of whom 3,059 received the 20-valent pneumococcal conjugate vaccine. There were no significant differences between the 20-valent pneumococcal conjugate vaccine and the 13-valent pneumococcal conjugate vaccine in adverse event incidence after doses 1-3 (risk ratio 1.00; 95%CI 0.92-1.10; p=0.952; I2=0%), or after dose 4 (risk ratio 0.90; 95%CI 0.76-1.07; p=0.238; I2=36%). Similarly, no significant differences were observed in serious adverse events, fever, irritability, and injection site pain. The 20-valent pneumococcal conjugate vaccine was associated with a higher incidence of decreased appetite after doses 2 (risk ratio 1.13, 95%CI 1.02-1.24; p=0.019) and 3 (risk ratio 1.34, 95%CI 1.14-1.58; p<0.001). In contrast, a significantly lower risk of local redness was observed with the 20-valent pneumococcal conjugate vaccine after dose 2 (risk ratio 0.93; 95%CI 0.86-0.99; p=0.034). The 20-valent pneumococcal conjugate vaccine demonstrated a safety profile largely comparable to the 13-valent pneumococcal conjugate vaccine, supporting its use in routine pediatric immunization programs.

PMID 43017995
Read full article →
PubMedAccess microbiology2026-11-12

Fluorinated galactose analogues inhibit Streptococcus pneumoniae biofilm formation.

Spencer Daniella L DL, Fairchild Charlotte C, Webb Jeremy S JS, Linclau Bruno B et al.

Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide, causing invasive diseases such as pneumonia, sepsis and meningitis, but also less severe localized infections like otitis media. To enable pneumococcal survival in the nutritionally challenging nasopharyngeal niche, it possesses an extensive repertoire of genes dedicated to the utilization of a wide range of carbohydrates. Galactose, the predominant carbohydrate found in the respiratory tract, is important in pneumococcal colonization and virulence and therefore represents an attractive target for the development of new treatments. In this preliminary study, we investigated the potential of fluorinated galactose analogues as a strategy for preventing and treating pneumococcal biofilms. The analogues were tested against planktonic pneumococci, and their effects on in vitro biofilms were assessed through biomass and viability measurements with validation through confocal and scanning electron microscopy. Their effect on adhesion of pneumococcus to Detroit562 pharyngeal epithelial cells and cytotoxicity was also assessed. Treatment with up to 2% wt/v galactose fluorinated at the C-3 (Gal-3F) and C-6 (Gal-6F) positions had no effect on final planktonic growth after 24 h within glucose-rich BHI medium; however, a reduction in mid-exponential growth rate was observed with 2% Gal-3F. Correlating with the transition towards biofilm formation involving a switch to galactose metabolism, 1-2% wt/v Gal-3F successfully inhibited biofilm formation for four out of five strains tested; however, no activity was observed against 48-h established biofilms, and there was no inhibition of epithelial adhesion. The equivalent concentrations of Gal-6F had no effect on pneumococcal biofilms, suggesting that the site of fluorination is important in activity. The inhibition of biofilm formation by Gal-3F confirms that targeting galactose metabolism is a potentially viable strategy for treating pneumococcal infection and that the rational design of fluorinated glycomimetics offers an alternative approach to targeting pneumococcal biofilms.

PMID 43016963
Read full article →
PubMedBMC public health2026-11-12

Evaluating parents' perceptions of infectious diseases and their levels of protection in terms of vaccination attitudes and vaccine hesitancy.

Gökçay Gönül G, Küçük Hulya Incirkuş HI, Sezer Nazlı Akar NA, Aydin Cansu Mine CM et al.

This research was conducted to evaluate parents' perceptions of infectious diseases and their levels of protection in terms of vaccination attitudes and vaccine hesitancy. The research is descriptive and relational was conducted online with 560 parents of children aged 0-5 years between March 8 and November 8, 2024. Convenience sampling method was used in the study. For data collection, a questionnaire form including personal information form, Perception Scale on Communicable Diseases (PSCD), Parental Attitudes Towards Childhood Vaccines Scale (PACVS), and Vaccine Hesitancy Scale (VHS) in parents of children under five years of age was used. The evaluation of data was performed via SPSS V-27.0 package program. A total of 560 parents took part in this study, and the participants scored an average of 148.81 ± 18.53 points on the PSCD total, 53.42 ± 8.91 points on the Vaccine Attitude Scale total, and 24.89 ± 8.49 points on the Vaccine Hesitancy Scale total. PSCD explains 13.4% of the total PACVS score. A low-level statistically significant correlation was found between the total PSCD and VHS scores. Parents' communicative disease perception and their protection levels affect their vaccination attitudes and vaccine hesitancy. Sociodemographic characteristics, vaccine knowledge and the sources from which they obtain information have both positive and negative relationships on vaccine attitude and vaccine hesitancy. In order to prevent the increasing vaccine refusal in the society, it is recommended that health professionals inform parents through individualized trainings on immunization.

PMID 43015717
Read full article →
PubMedBMC infectious diseases2026-11-12

Human papillomavirus vaccine acceptability in Cameroon: a systematic review and meta-analysis.

Cheuyem Fabrice Zobel Lekeumo FZL, Achangwa Chabeja C, Tchamani Rick R, Tsapi Armand Tiotsia AT et al.

Human papillomavirus (HPV) vaccination is a key strategy for cervical cancer elimination. In Cameroon, HPV vaccine was introduced into the expanded program on immunization in 2020. However, synthesized evidence on vaccine acceptability is needed to guide policy. This systematic review and meta-analysis aimed to estimate the pooled prevalence of HPV vaccine knowledge, willingness to vaccinate, recommendation practices, and actual uptake in Cameroon, and to identify determinants of vaccine hesitancy. We searched PubMed, Scopus, Web of Science, Embase, Cochrane Library, and African Journals Online from studies to January 2025. Studies reporting willingness to vaccinate, knowledge, recommendation, and uptake of HPV vaccine were included. Pooled prevalence estimates and odds ratios were calculated using random-effects models. Heterogeneity was assessed using the I² statistic. The study was reported following PRISMA 2020 guidelines and registered in PROSPERO ID: CRD420261301213. Thirty-three studies were included. Among 4,993 participants, who were mainly healthcare workers (n = 1,739) and parents (n = 2,419), the pooled prevalence of willingness to vaccinate was 68.1% (95% confidence interval [CI]: 57.4-77.2; 12 studies; I² = 98%). The pooled prevalence of HPV vaccine knowledge was 41.3% (95% CI: 28.7-55.1; 33 studies; n = 8,175 participants; I² = 98%). Approximately two-thirds of participants (67.7%; 95% CI: 50.7-81.0; 8 studies; n = 1,617) reported recommending the vaccine, but actual uptake was 22.9% (95% CI: 6.9-54.5; 9 studies; n = 9,686). The vaccine coverage ranged from 1.6% to 90.6%. Willingness significantly declined from 74.2% before 2014 to 57.5% after 2021. Healthcare workers had the highest knowledge (74.5%) and willingness (77.8%) among included participant groups. Lack of HPV knowledge was associated with nearly three-fold higher hesitancy (odds ratio [OR]: 2.58; 95% CI: 2.06-3.22). High heterogeneity was observed for all pooled estimates, suggesting that they should be interpreted as average estimates rather than precise values. Despite moderate willingness, HPV vaccine knowledge and uptake remain low in Cameroon, with marked disparities across regions and populations. Addressing knowledge gaps and strengthening context-specific vaccination strategies are needed to improve coverage.

PMID 43015661
Read full article →
PubMedAIDS reviews2026-11-12

Herpes zoster vaccination in people living with HIV: from evidence to implementation - A narrative review.

Van Nguyen Hung H, Thi Diem Le Trinh T

Herpes zoster (HZ) remains a significant, preventable cause of morbidity among people living with HIV (PLWH), who face increased risks of HZ, recurrence, and complications despite effective antiretroviral therapy. The recombinant zoster vaccine (RZV), a non-live, adjuvanted vaccine, is currently the preferred strategy for HZ prevention in immunocompromised adults. This narrative review synthesizes the evidence on the burden and pathogenesis of HZ in PLWH, RZV immunogenicity and safety, present vaccination recommendations, clinical considerations, and implementation challenges, with particular emphasis on the Asia-Pacific region. Available evidence indicates that RZV induces robust humoral and cellular immune responses and has a favorable safety profile in PLWH; however, HIV-specific evidence regarding clinical effectiveness, long-term durability of protection, and optimal timing of vaccination in the setting of advanced immunosuppression remains limited. International guidelines consistently recommend a two-dose RZV series for adults with HIV, without requiring a specific CD4+ T-cell threshold or virological suppression. Nevertheless, vaccine uptake remains constrained by cost, limited availability, inadequate patient and healthcare-provider awareness, vaccine hesitancy, and fragmented vaccination services. Future research should prioritize real-world effectiveness, durability of protection, cost-effectiveness, and determinants of vaccine acceptance, including behavioral factors, such as perceived susceptibility, perceived benefits, and perceived barriers. Integrating RZV into routine HIV care and strengthening implementation strategies, particularly across the Asia-Pacific region and other resourcelimited settings, will be critical to translating guideline recommendations into equitable vaccination coverage and reducing HZ-related morbidity among PLWH.

PMID 43018275
Read full article →
PubMedBiomedical and environmental sciences : BES2026-11-12

Broadening Vaccine Value: Translating Comprehensive Assessment into Sustained Population Protection.

Wang Hua Qing HQ

PMID 43016181
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about pneumococcal vaccine